Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.

Thongprayoon C, Acharya P, Aeddula NR, Torres-Ortiz A, Bathini T, Sharma K, Ungprasert P, Watthanasuntorn K, Suarez MLG, Salim SA, Kaewput W, Chenbhanich J, Mao MA, Cheungpasitporn W.

Arch Osteoporos. 2019 Mar 9;14(1):35. doi: 10.1007/s11657-019-0587-0. Review.

PMID:
30852679
2.

Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.

Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, Sharma K, Wijarnpreecha K, Ungprasert P, Gonzalez Suarez ML, Cheungpasitporn W.

Osteoporos Int. 2018 Aug;29(8):1737-1745. doi: 10.1007/s00198-018-4533-6. Epub 2018 Apr 30. Review.

PMID:
29713798
3.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

4.

Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.

Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M.

Osteoporos Int. 2019 Jan;30(1):241-249. doi: 10.1007/s00198-018-4688-1. Epub 2018 Sep 5.

PMID:
30187112
5.

Effect of Twice-Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial.

Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, von Eckardstein A, Graf N, Wüthrich RP.

Am J Transplant. 2016 Jun;16(6):1882-91. doi: 10.1111/ajt.13692. Epub 2016 Feb 29.

6.

Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients
.

Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T.

Clin Nephrol. 2019 Apr 16. doi: 10.5414/CN109723. [Epub ahead of print]

PMID:
30990412
7.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

8.

Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.

Dave V, Chiang CY, Booth J, Mount PF.

Am J Nephrol. 2015;41(2):129-37. doi: 10.1159/000380960. Epub 2015 Mar 18.

PMID:
25790847
10.

Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab.

Mosali P, Bernard L, Wajed J, Mohamed Z, Ewang M, Moore A, Fogelman I, Hampson G.

Calcif Tissue Int. 2014 May;94(5):553-9. doi: 10.1007/s00223-014-9840-0. Epub 2014 Feb 8.

PMID:
24509506
11.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

12.

Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials.

Palmer SC, Strippoli GF, McGregor DO.

Am J Kidney Dis. 2005 Apr;45(4):638-49. Review.

PMID:
15806466
13.

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women.

Augoulea A, Tsakonas E, Triantafyllopoulos I, Rizos D, Armeni E, Tsoltos N, Tournis S, Deligeoroglou E, Antoniou A, Lambrinoudaki I.

J Musculoskelet Neuronal Interact. 2017 Mar 1;17(1):444-449.

15.

Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status, pregnancy, and lactation.

Ghannam NN, Hammami MM, Bakheet SM, Khan BA.

Calcif Tissue Int. 1999 Jul;65(1):23-8.

PMID:
10369729
16.

Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials.

Mitterbauer C, Schwarz C, Haas M, Oberbauer R.

Nephrol Dial Transplant. 2006 Aug;21(8):2275-81. Epub 2006 Mar 30.

PMID:
16574684
17.

Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis.

Toth-Manikowski SM, Francis JM, Gautam A, Gordon CE.

Clin Transplant. 2016 Sep;30(9):1090-6. doi: 10.1111/ctr.12792. Epub 2016 Jul 19. Review.

PMID:
27327448
18.

Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.

Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.

Ther Clin Risk Manag. 2018 Jul 10;14:1213-1218. doi: 10.2147/TCRM.S167579. eCollection 2018.

19.

Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.

Cheng BC, Chen YC.

Clin Rheumatol. 2017 Apr;36(4):929-932. doi: 10.1007/s10067-016-3447-y. Epub 2016 Oct 18.

PMID:
27757701
20.

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.

Nakamura Y, Kamimura M, Morikawa A, Taguchi A, Suzuki T, Kato H.

Ther Clin Risk Manag. 2018 Mar 14;14:543-549. doi: 10.2147/TCRM.S156466. eCollection 2018.

Supplemental Content

Support Center